Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose inhaled ETD001 in adults with cystic fibrosis
ISRCTN11798668Phase 2Completed
- Sponsor
- Enterprise Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ETD001 in cystic fibrosis (CF) (4 arms), sponsored by Enterprise Therapeutics. Started Jun 2024; status: completed.
02
Drugs
ETD001
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ISRCTN11798668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11798668.